
Decreasing Use of Luteinizing Hormone-Releasing Hormone Agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration Claims Analysis
Keywords: physician's practice patterns; prostatic neoplasms; antineoplastic agents; gonadotropin-releasing hormone; Medicare; ADT; androgen deprivation therapy; BESS; Part B Extract Summary System; CMS; Centers for Medicare and Medicaid Services; FDA; Food and Dru